Founded in 2016, PolarityTE (Nasdaq:PTE), a company focused on developing regenerative tissue products to address unmet medical needs in chronic wounds, has recently commenced a Phase 3 pivotal study involving patients with diabetic foot ulcers (DFUs).  In addition, the FDA granted its investigational SkinTE product Regenerative Medicine Advanced Therapy (RMAT) designation.  PTE shares, however, skidded…